en Español Drug Safety Conversation (PDF – 197 KB) 6-1-2022 Food and drug administration Drug Security Communication Due to safety considerations, the U.S. Food and Drug Administration (Fda) has withdrawn its approval for the cancer medicine Ukoniq (umbralisib). Ukoniq was authorized to handle two unique types of lymphoma: marginal zone […]
Saturday, Oct 31, 2026
Breaking News